ClinicalTrials.Veeva

Menu

Serum miR-455-5p and Cardiac Structure and Function Parameters in Patients With Hypertensive Heart Disease

T

The University of Hong Kong-Shenzhen Hospital

Status

Invitation-only

Conditions

Hypertension
Heart Disease

Study type

Observational

Funder types

Other

Identifiers

NCT07033676
82300446 (Other Grant/Funding Number)
RCBS20231211090745071 (Other Grant/Funding Number)
2022A1515111093 (Other Grant/Funding Number)
caisd@hku-szh.org

Details and patient eligibility

About

Hypertensive heart disease (HHD) is the leading cause of mortality and morbidity worldwide. In 2017, the prevalence of HHD worldwide was 217.9 per 100,000 people, an increase of 7.4% over 1990, which has brought huge financial burden and social and economic losses to the world. Therefore, HHD is a major public health challenge worldwide. In our previous studies, we found that miR-455-5p, a microRNA, could functioned as an inducer to promote cardiac hypertrophy. Because cardiac hypertrophy was a common phenomenon in patients with HHD, so it is interesting to clarify whether miR-455-5p could be employed as a marker to indicate the function and/or structure of heart in the development of HHD. Thus, the purpose of this study was to collect blood samples of hypertensive patients, as well as analysis the correlation between serum miR-455-5p level and cardiac function. The research could help doctors better predict the course of hypertensive heart disease and provide more effective treatments for different patients.

Full description

The purpose of this study was to collect blood samples of hypertensive patients, in order to clarify the correlation between serum miR-455-5p level and cardiac function. Generally, by using q-PCR assay, miR-455-5p level of each participants will be collected. Besides, SBP, DBP, LVPWd, LVIDd, IVSTd was detected by echocardiography and EF, FS, LVMi, RWT level was further calculated by LVIDd, LVPWd and IVSTd. Finally, the correlation of miR-455-5p level of HHD patients and LVPWd, LVIDd, IVSTd, EF, FS, LVMi, RWT, SBP, DBP was analysed.

Enrollment

46 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

    1. age ≥18 years; 2. male or female; 3. systolic blood pressure ≥140mmHg or (and) diastolic blood pressure > 90mmHg; 4. history of hypertension>1year, NYHA grade I-IV

Exclusion criteria

  • hypertensive heart diseases patients with other metabolic diseases or congenital diseases were excluded from the study

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems